Praluent (Alirocumab): Legal Challenges, Patent Battles, and Regulatory History

Alirocumab, sold under the brand name Praluent, is a fully human monoclonal antibody in the PCSK9 inhibitor class, given by subcutaneous injection. It is not the same molecule as evolocumab (Repatha), a competing PCSK9 antibody made by Amgen, or inclisiran (Leqvio), a PCSK9-targeting small interfering RNA with a different dosing schedule. This article covers Praluent's FDA approval history, the patent litigation between Amgen and Sanofi/Regeneron that reached the U.S. Supreme Court, and what has and has not changed for patients as a result.

The core point of this page: Praluent's regulatory story and its patent story are two separate timelines that get conflated. The FDA approval, label expansion for cardiovascular risk reduction, and safety monitoring ran on their own track based on clinical trial data. The Amgen v. Sanofi patent fight was a business dispute over antibody patent claims that never changed what the drug does or who it is approved for. As of this writing, patients and clinicians should treat the Supreme Court's 2023 ruling as having removed a commercial threat to the manufacturer, not as new clinical evidence, and should not assume the price cut or the litigation outcome changed insurance prior authorization rules, which remain governed separately by payer policy.

What is actually established about Praluent's approval

The FDA approved alirocumab in 2015, and it was among the first PCSK9 inhibitors to reach the U.S. market. The original approval covered adults with heterozygous familial hypercholesterolemia (HeFH) and adults with established atherosclerotic cardiovascular disease (ASCVD) who needed additional LDL-C lowering beyond maximally tolerated statin therapy. The current FDA label, available directly from the agency, is the authoritative source for exact indications, dosing, and safety language.

Alirocumab's approved uses expanded following the ODYSSEY OUTCOMES trial, which evaluated patients in the period after acute coronary syndrome. The trial showed a hazard ratio near 0.85 for the composite cardiovascular endpoint and an absolute event rate difference of roughly one to two percentage points over approximately 2.8 years of median follow-up, confirming cardiovascular risk reduction as an indication. These topline figures align with publicly available trial data, though specific numbers from secondary sources should be verified against the original New England Journal of Medicine report if they will appear in patient-facing materials. Alirocumab also received approval for homozygous familial hypercholesterolemia (HoFH) in patients aged 8 and older. Because HoFH is uncommon, prescribers should apply specialist judgment to dosing decisions in pediatric patients rather than relying on standard dosing ranges.

Injection-site reactions are the most consistently reported adverse effect. A theoretical concern about neurocognitive effects (because cholesterol is a component of myelin) has been studied, and available reporting has not shown a clear signal distinguishing alirocumab from placebo, but readers should treat this as reassuring rather than as proof of long-term absence of risk, since post-market surveillance continues.

The Amgen v. Sanofi patent dispute, separated from the clinical story

Amgen, which markets the competing PCSK9 antibody evolocumab, held patents claiming a broad genus of antibodies that bind PCSK9 in a way that blocks its interaction with the LDL receptor. Amgen sued Sanofi and Regeneron, arguing that alirocumab fell within that genus. The case went through a jury verdict, an appellate reversal, a second trial, and ultimately reached the U.S. Supreme Court.

In June 2023, the Supreme Court ruled unanimously that Amgen's broad genus claims were not adequately enabled under patent law, because Amgen had described only a small number of specific antibodies while claiming rights over a functional category that could include a much larger, unspecified set of molecules. The opinion is a matter of public record from the Supreme Court itself; readers who want the primary text should look to the Court's own published opinion rather than a secondary medical database, since some citation trails for this case circulating online misattribute it to biomedical journal archives.

This ruling had a specific, narrow legal effect: it removed the risk that a U.S. court would order Praluent off the market or impose an injunction based on Amgen's patents. It did not add or remove any clinical indication, and it did not by itself change insurance coverage rules.

Did the price cut and litigation outcome change patient access?

Not directly, and this is the point most likely to be misunderstood. Praluent launched at a wholesale acquisition cost widely reported to be in the range of $14,000 or more per year, well above the cost-effectiveness benchmarks published around that time by independent value assessment groups. In 2019, the manufacturers announced a substantial list price reduction, commonly reported as around 60 percent, bringing the WAC down to roughly $5,000 to $6,000 per year. That price reduction was announced separately from, and years before, the 2023 Supreme Court ruling; it was driven by payer pushback and value-based pricing pressure, not by the patent litigation outcome.

Prior authorization remains common for PCSK9 inhibitors in the U.S. regardless of the 2019 price cut or the 2023 patent ruling. Insurers generally still require documentation of statin intolerance or an inadequate LDL-C response on maximally tolerated statin therapy, along with a confirmed ASCVD or familial hypercholesterolemia diagnosis, before approving coverage. Readers should verify current prior authorization criteria with their own insurer, since these rules change over time and are set by individual plans rather than by the FDA or the courts.

Evidence boundary: what this history does and does not tell you

Established: Praluent received FDA approval in 2015 for HeFH and ASCVD, later gained a cardiovascular risk reduction indication and a pediatric HoFH indication, and the 2023 Supreme Court decision in Amgen v. Sanofi resolved the genus-claim patent dispute in Sanofi and Regeneron's favor. A 2019 list price reduction of roughly 60 percent is well documented.

Plausible but requiring primary-source verification before quoting exact figures: the specific hazard ratios, percentage event rates, and subgroup mortality figures from the cardiovascular outcomes trial, and any specific current sales or market-share numbers for Praluent versus Repatha. These should be checked against the original trial publication and current company financial filings rather than repeated from secondary summaries.

Not established by anything in this history: that the patent ruling or price cut changed individual insurance prior authorization outcomes, that achieving very low LDL-C on alirocumab is itself harmful, or that alirocumab is interchangeable with evolocumab or inclisiran for a given patient without a clinician's assessment of dosing schedule, formulary coverage, and comorbidities.

A framework for sorting "is this a legal issue or an access issue?"

Patients, caregivers, and even some clinicians conflate patent litigation, regulatory approval, and insurance coverage when trying to understand why a drug is hard to get or what a court ruling means for them. Use this to sort a specific question before searching further:

If your underlying question is about affordability or coverage, the patent history is background, not the lever to pull. The lever is your insurer's prior authorization process and any manufacturer copay assistance program, verified directly rather than assumed from litigation news.

When to involve a clinician rather than rely on this history

This page does not include dosing information. Patients should notify their prescriber promptly if they develop new muscle pain, injection site allergic reactions, unusual bruising, or cognitive changes during alirocumab treatment. Anyone who experiences chest pain, sudden weakness, or stroke symptoms should call emergency services immediately, independent of their current medications. Treatment decisions regarding initiation, discontinuation, or switching to another PCSK9 inhibitor require input from the prescribing clinician, who can consider the patient's LDL-C trajectory, overall cardiovascular risk, and insurance coverage. Regulatory approval information alone is not sufficient for these clinical decisions.